[{"address1": "The MediaWorks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 59, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 2739095, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 51, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 58, "title": "Senior VP & COO", "yearBorn": 1965, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Brochu", "age": 67, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1956, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brent  Rice", "age": 57, "title": "Senior VP, Chief Commercial Officer & Site Head of US", "yearBorn": 1966, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Edgar E. W. Braendle M.D., Ph.D.", "age": 63, "title": "Senior VP & Chief Development Officer", "yearBorn": 1960, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert F. Dolski", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Driggs", "title": "Senior VP of Legal Affairs & General Counsel and Secretary", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Swan", "title": "Chief Human Resources Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.7, "open": 5.7, "dayLow": 5.525, "dayHigh": 5.87, "regularMarketPreviousClose": 5.7, "regularMarketOpen": 5.7, "regularMarketDayLow": 5.525, "regularMarketDayHigh": 5.87, "beta": 1.893, "forwardPE": -14.195123, "volume": 2012513, "regularMarketVolume": 2012513, "averageVolume": 1738837, "averageVolume10days": 1382060, "averageDailyVolume10Day": 1382060, "bid": 5.38, "ask": 5.39, "bidSize": 1400, "askSize": 900, "marketCap": 1352114048, "fiftyTwoWeekLow": 1.61, "fiftyTwoWeekHigh": 7.45, "priceToSalesTrailing12Months": 796.29803, "fiftyDayAverage": 6.208, "twoHundredDayAverage": 4.02505, "currency": "USD", "enterpriseValue": 773671040, "floatShares": 77446475, "sharesOutstanding": 232322000, "sharesShort": 2769469, "sharesShortPriorMonth": 2938957, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0119, "heldPercentInsiders": 0.20646, "heldPercentInstitutions": 0.60338, "shortRatio": 1.24, "shortPercentOfFloat": 0.0199, "impliedSharesOutstanding": 232322000, "bookValue": 0.64, "priceToBook": 9.09375, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -208383008, "trailingEps": -0.98, "forwardEps": -0.41, "enterpriseToRevenue": 455.637, "enterpriseToEbitda": -4.574, "52WeekChange": 1.8252428, "SandP52WeekChange": 0.29495108, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AUTL", "underlyingSymbol": "AUTL", "shortName": "Autolus Therapeutics plc", "longName": "Autolus Therapeutics plc", "firstTradeDateEpochUtc": 1529674200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "da5466ad-c9a9-3bae-a4e5-c7afee3582d0", "messageBoardId": "finmb_562879769", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.82, "targetHighPrice": 13.0, "targetLowPrice": 5.0, "targetMeanPrice": 9.66, "targetMedianPrice": 10.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 239566000, "totalCashPerShare": 1.376, "ebitda": -169141328, "quickRatio": 5.355, "currentRatio": 6.154, "totalRevenue": 1698000, "revenuePerShare": 0.01, "returnOnAssets": -0.25346002, "returnOnEquity": -1.01614, "revenueGrowth": -1.0, "operatingMargins": -103.37338, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-17"}]